Novartis and Viatris latest facing lawsuit over HeLa cell misuse
![](/46/pdcnewsitem/12/50/69/Heading%20image%20(21).png)
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent.
The HeLa cell line was created from cancerous cervical cells harvested from Henrietta Lacks, an African-American woman treated for cervical cancer at John Hopkins Hospital in Baltimore, Maryland in 1951. What makes the HeLa cell line so powerful are the cells’ ability to survive and reproduce indefinitely in lab conditions. Previous cells cultured from human cells would only live for a few days, whereas HeLa cells can be used for extensive studies due to their proliferation. HeLa cells have been behind some of the biggest medical advances in history, such as the development of a polio vaccine and in cancer studies.
As was common practice in the mid-20th century, Lacks was not informed of the cell harvesting, nor of their use in scientific studies. Her family was not made aware of their usage until the 1970s. Lacks eventually died of cervical cancer in 1951, aged 31. Her story continues to be a major example of privacy concerns and patient rights in medical research.
In their latest suit brough against Novartis and Viatris, the estate of Henrietta Lacks claims that the companies are unlawfully profiting from the use of HeLa cells in the creation of profitable drug products without gaining permission from or giving monetary compensation to her estate. Previous lawsuits from the estate were brought against companies such as Thermo Fisher and Ultragenyx, the former of which has since been settled. The estate claims that Novartis’ herpes drug Famvir, cancer treatment Kymriah, and spinal muscular atrophy therapy Zolgensma all used HeLa cells in their development and research. Viatris is being accused of misusing the cell line in the testing of herpes drug Denavir and depression treatment Mylan-Mirtazapine. Spokespeople for both companies declined to comment on the lawsuits.
The estate claim Lacks’ cells were exploited for research purposes and profited from by powerful organisations against her and her family’s will, and are requesting that any company profiting from commercialised products using HeLa cells be donated to her estate, and a court order blocking HeLa cell use without their permission.
Source:
Novartis, Viatris face new lawsuit over ‘HeLa’ cell misuse claims [Accessed August 6, 2024] https://www.reuters.com/legal/novartis-viatris-face-new-lawsuit-over-hela-cell-misuse-claims-2024-08-05/
Related News
-
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Alzheimer’s drug Leqembi rejected by EU drug regulator
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin... -
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Reworked once-daily weight-loss pill from Pfizer to progress
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. -
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance